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Abstract The mechanisms of HIV-1 neurotoxicity remain still 
undefined although the induction of signalling events and a 
modest inhibition of glutamate uptake induced by the envelope 
glycoprotein, gpl20, have called attention to astrocytes. Here we 
demonstrate that the levels at which the viral glycoprotein affects 
glutamate homeostasis of astrocyte cultures are at least two: not 
only the inhibition of uptake, due to an effect at site(s) away from 
the transporters of the amino acid but also a slow stimulation of 
release. The combination of these two events accounts for a 
considerable steady increase of the extracellular concentration of 
the excitatory amino acid which could play an important role in 
the neurotoxicity often observed in AIDS patients. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Neurological disorders characterized by impairment of cog-
nition and motor performance have often been reported in 
patients infected by the human immunodeficiency virus type 
1, HIV-1 [1]. In many such cases the brain infection, although 
confined to macrophages and microglia [1,2], was accompa-
nied by striking losses of neurons [3,4]. Death of the latter 
cells appears therefore to develop indirectly, most likely via 
shedding of injurious proteins from infected cells. In previous 
studies, the HIV-1 coat protein gpl20 was shown to be neuro-
toxic in vivo, both when injected intracerebrally [5] and when 
expressed by astrocytes in transgenic mice [6]. Moreover, in 
mixed cultures of neurons and glia the gpl20-induced neuro-
toxicity was prevented by NMDA receptor antagonists [7,8], 
suggesting the sensitization of these receptors to the activation 
by endogeneous glutamate. Whether these effects are due to a 
direct action of gpl20 on neurons [9,10] or require the in-
volvement of other cells, not only the infected microglia and 
monocytes [11] but possibly also astrocytes [7,12], remains 
debated (for reviews see [2] and [13]). A role of astrocytes is 
suggested by a multifarious experimental evidence. Exposure 
to gpl20 induces in these cells a number of signalling events 
such as increases of [Ca2+]; [14,15] and of protein tyrosine 
phosphorylation [15]; depolarization [16]; activation and re-
distribution of protein kinase C [17] as well as inhibition of 
glutamate uptake [16] mediated via microglia-released arach-
idonic acid [18]. Whether the above effects constitute the en-
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tire spectrum induced by gpl20 in astrocytes has not been 
established yet. 
By using primary astrocyte cultures we demonstrate here 
that the action of subnanomolar concentrations of gpl20 on 
glutamate control by astrocytes is more complex than previ-
ously envisaged since it includes not only a blockade of up-
take but also a stimulation of release. The overall consequence 
of these processes, the rise of extracellular glutamate, [Glu]0, 
could have an important role in the chain of events leading to 
widespread damage of brain cells, as observed in the course of 
HIV-1 infection. 
2. Materials and methods 
2.1. Cell cultures 
Confluent monolayers of rat cortical astroglial cells were obtained 
as previously described [19] and plated in 35 mm Petri dishes. They 
were enriched (>97%) in flat type-1 astrocytes. For fluorometric de-
terminations in continuous, cultures were plated on coverslips sized to 
fit into the instrument cuvettes. 
2.2. /3HJGlutamate uptake 
In order to assay uptake into astrocytes [20] cell monolayers were 
incubated for 60 min in the presence of gpl20 or other agents in a 
buffer containing (mM): 25 glucose, 1.8 CaCl2, 1 MgCl2, 4 KC1, 116 
NaCl, 10 HEPES, pH 7.4, and supplemented with 10 uM 
[3H]glutamate (53 Ci/mmol, isotopic dilution 1/4000). 5 min later 
the cells were rapidly washed with ice-cold buffer containing excess 
glutamate, scraped from the culture dishes with NaOH (0.2 N) and 
counted by liquid scintillography for incorporated radioactivity. 
To assay transport into liposomes, glutamate transporters from rat 
forebrain were partially purified and reconstituted as described [21]. 
This preparation contains immunoreactivity to the GLT1, GLAST 
and EAAC1 transporter subtypes [22], Proteoliposomes with KPi as 
their internal medium were pre-incubated in a phosphate buffer pH 
7.4 (containing 130 mM NaCl, 20 mM NaP; and 1% glycerol) ± gpl20 
for 15 min, after which uptake was started by the addition of 1.4 uCi 
of [3H]glutamate+2.8 uM valinomycin. 70 s later liposomes were col-
lected on filters and counted for radioactivity. 
2.3. Fluorometric assay of [Glu]0 
Astrocyte cultures were incubated for 60 min in HEPES buffer (see 
above) ± different agents. At the end, incubation media were collected 
and their [Glu]0 measured by means of a specific fluorescence assay 
(excitation and emission at 335 and 430 nm, respectively) performed 
at 37°C in a Perkin-Elmer LS50B computerized spectrofluorometer 
[23]. Samples (1 ml) were transferred to a cuvette containing gluta-
mate dehydrogenase (GDH, 40 U/ml, Sigma G2626, batch 64H7130) 
and 1 mM NADP+. Glutamate oxidation by GDH to a-ketoglutarate 
led to formation of NADPH with fluorescence emission. [Glu]0 was 
calculated by referring to standard curves constructed with exogenous 
glutamate (in the linear range 0.1-1 |iM) and by normalizing for the 
protein content of each sample. 
In order to monitor continuously the endogenous glutamate release, 
glass coverslips with cultured astrocytes were lodged in a 1 X 1 cm cu-
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vette (2 ml volume) inside the spectrofluorometer in HEPES buffer and 
incubated at 37°C under stirring. gpl20 and other agents were added 
directly to the cuvette via a microsyringe. Unidirectional glutamate 
efflux was monitored in continuous by the enzymatic assay described 
above which ensures immediate reaction of cell-released glutamate with 
GDH, thereby preventing the reuptake process. Efflux, here expressed 
as nmol glutamate released/mg prot, was calculated as above. 
2.4. Materials 
Recombinant gpl20 was purchased from Intracel (London, UK); 
[3H]glutamate from Amersham International; MEM, FCS, penicillin/ 
streptomycin and glutamine for cell cultures from ICN Flow (Costa 
Mesa, CA); dihydrokainate (DHK) and all other chemicals from 
Sigma. 
3. Results and discussion 
In agreement with previous reports [18,24] native (but not 
heat-inactivated) gpl20 was found to induce a slight, but sig-
nificant reduction (—15 ±3%, « = 5) of [3H]glutamate uptake 
into cultured cortical astrocytes (Fig. 1). In contrast, the viral 
protein had no appreciable effect on the purified brain gluta-
mate transporters functionally reconstituted in liposomes 
(n = 3, not shown). As this preparation is enriched in GLT1 
and also contains GLAST [22], the two glial transporters, we 
conclude that inhibition by gpl20 is not due to a direct inter-
action with these specific targets (see also [18]). 
To study whether the uptake inhibition by gpl20 is paral-
leled by the elevation of [Glu]0 of astrocyte cultures, medium 
assays were carried out at the end of the 60 min incubation 
with 200 pM of the viral protein. To our surprise, the same 
treatment that reduced uptake only slightly was able to almost 
double the [Glu]0 of the cultures (n = 8). In contrast, equimo-
lar boiled gpl20 had almost no effect (Fig. 2). 
To clarify whether uptake inhibition was indeed responsible 
for the marked [Glu]0 enhancement by gpl20, parallel experi-
Fig. 1. Inhibition of glutamate uptake into cultures of cortical astro-
cytes by gpl20 and DHK. 100% uptake of [3H]glutamate was 
55 800 ±1000 cpm. Results shown are averages ± S.E.M. of 3-5 ex-
periments. *, P < 0 . 0 1 , one-way ANOVA followed by the Tukey 
method for multiple comparisons. 
ments were performed using a specific glutamate uptake 
blocker drug, DHK [25]. In contrast to most other blockers 
including the potent Z-pyrrolidine-2,4-dicarboxylate, DHK is 
known to block uptake without being transported and there-
fore cannot be exchanged with cytosolic glutamate during the 
transport process [19]. Because of this property (see also Fig. 
3, insert), DHK appears well suited to identify the contribu-
tion of the uptake inhibition process to [Glu]0 increase. 1 h 
incubation with 2 mM DHK, on the one hand induced uptake 
inhibition stronger than gpl20 (« = 3, Fig. 1); on the other 
hand, enhanced [Glu]Q only slightly (« = 6, Fig. 2). Thus, the 
larger [Glu]Q elevation of gpl20 necessarily requires additional 
mechanisms. 
The effect of the protein on the release of glutamate from 
astrocytes was next investigated. For this purpose, the enzy-
matic assay of Nicholls and Sihra [23] was modified to con-
tinuously monitor the unidirectional efflux of glutamate from 
our cultures. Fig. 3 shows that addition of 200 pM gpl20 after 
a 40 min recording of baseline enhanced, slowly but consis-
tently, the release of glutamate for about 70 min. When em-
ployed at 1 nM, the total release induced by gpl20 was similar 
but the rate was faster as the process lasted about 40 min. At 
the two concentrations release took place in fact at 0.017 and 
0.031 nmol/min/mg protein, respectively. No significant en-
hancement from basal release was observed after addition of 
either equimolar boiled gpl20 (» = 3, not shown) or 2 mM 
DHK (Fig. 3, insert). This last observation is important, as 
it confirms that in our assay glutamate release is specifically 
revealed, without contribution of uptake. 
In conclusion, our data indicate that gpl20 markedly ele-
vates [Glu]0 of astrocyte cultures by two parallel mechanisms: 
(a) activation of a slow release process; (b) inhibition of up-
take. The mechanism of release remains to be understood and 
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Fig. 2. [Glu]0 increases induced by gpl20 and DHK in cultures of 
cortical astrocytes. Basal [Glu]0 was 451 ± 32 nM. Results shown are 
averages ± S.E.M. of 6-8 experiments. **, P< 0.001; *, P < 0 . 0 1 , 
one-way ANOVA followed by the Tukey method for multiple com-
parisons. 
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Fig. 3. Glutamate release from cultures of cortical astrocytes as revealed in continuum by the GDH fluorescence procedure. Administration of 
DHK and gpl20 at time 0 are indicated by an arrow in the small and large panel, respectively. The arrows with indications of DHK, gpl20 
and CTRL identify the treatments (with doses) and the controls. Overall glutamate release values were (in nmol/mg protein): 0.337±0.017 for 
control (n = 4); 0.34±0.023 for DHK (» = 3)-, 1.167±0.07 gpl20 (200 pM, n = l)- and 1.22±0.2 for gpl20 (1 nM, n = 3)-treated samples. 
could be peculiar. So far, in fact, at least two processes, one 
Ca2 +- independent , the other Ca2 +-dependent , have been de-
scribed, activated in response to swelling or neuroligands 
[26,27]. Both of them, however, occur at rates much faster 
than those observed here. With gpl20 , on the other hand, 
[Glu]0 remains elevated at the end of the incubation, most 
likely because the enhanced release is not compensated by 
adequate uptake. The duality of the gpl20 action might there-
fore ultimately induce synergistic effects on glutamate homeo-
stasis. Since in the brain astrocytes are intimately connected to 
neurons and synapses, the effects of gp l20 here observed on 
astrocyte cultures could have important toxic consequences. 
The raised ambient glutamate levels, even if of moderate ex-
tent, might in fact induce in the long run injurious overacti-
vation of neuronal excitatory amino acid receptors, a process 
already suggested to play a key role in the development of 
gpl20-mediated neurotoxicity [7,8]. 
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